Document Detail


The effect of verapamil on left ventricular remodelling and diastolic function after acute myocardial infarction (the Verapamil Infarction Study on Remodelling and Relaxation--VISOR).
MedLine Citation:
PMID:  10516867     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The VISOR is a double blind, randomized, placebo-controlled study aimed to assess the effects of early and prolonged administration of verapamil on the left ventricular geometry and diastolic function in patients with anterior acute myocardial infarction treated with thrombolysis. Patients with heart failure or ejection fraction < 45% were excluded. Within 12 hours from starting thrombolysis, 70 patients were given verapamil (5 mg/hour intravenously for the first 24 hours, followed by 120 mg t.i.d. perorally for 6 months) or equivalent placebo. Echocardiograms were performed on admittance, before discharge, after 3 months and 6 months. The following parameters were calculated: left ventricular volumes, ejection fraction, sphericity index, early (E) and late (A) transmitral peak flow velocities and time-velocity integrals with their ratios, deceleration time and half-time of E, isovolumic relaxation time (IVRT), and non-invasive time constant of ventricular relaxation (tau). The basal and the last available parameters were considered for statistical analysis. The effects of the treatment on the left ventricular volumes, ejection fraction, and sphericity index were not statistically relevant. Conversely, a reduction of E/A ratio (P < .05) and increases of A integral (P < .01), deceleration time and half-time of E, IVRT and tau (P < .05) were found in the placebo group and not in the verapamil group. No significant changes in the blood pressure, heart rate, PQ interval, and biochemical parameters were observed in the two groups. In conclusion, in patients with a thrombolysed anterior acute myocardial infarction and preserved systolic function, verapamil can prevent alterations of the diastolic function in absence of effect on ventricular remodelling, and has a good safety profile.
Authors:
E Natale; M Tubaro; G Di Marcotullio; P Celli; M Carelli; U Malinconico; C A Polizzi; F Milazzotto; S F Vajola
Related Documents :
15034157 - Improvement of cardiac function after haemodialysis. quantitative evaluation by colour ...
22297077 - Diagnostic value of morphometry in feline hypertrophic cardiomyopathy.
1409217 - Doppler echocardiographic evaluation of left ventricular diastolic function in patients...
7963017 - Effect of collagen on the anisotropy of quasi-longitudinal mode ultrasonic velocity in ...
9822047 - Contrast echoes detected during percutaneous mitral balloon commissurotomy with inoue b...
16253067 - Innovative technique for ureteral stenting during retroperitoneal laparoscopic ureterol...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  13     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1999 Jul 
Date Detail:
Created Date:  1999-11-30     Completed Date:  1999-11-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  315-24     Citation Subset:  IM    
Affiliation:
Coronary Care Unit, San Camillo Hospital, Rome, Italy. ENRICO.NATALE@flashnet.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Calcium Channel Blockers / administration & dosage,  therapeutic use
Diastole / drug effects*
Double-Blind Method
Echocardiography
Echocardiography, Doppler
Electrocardiography / drug effects
Female
Hemodynamics / drug effects*
Humans
Male
Middle Aged
Myocardial Infarction / pathology*
Time Factors
Ventricular Remodeling / drug effects*
Verapamil / administration & dosage,  therapeutic use*
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early treatment with verapamil or diltiazem in patients with acute myocardial infarction: safety and...
Next Document:  Disopyramide decreases the fasting serum glucose level in man.